ConductScience.org, home

Comparison · NCT01585441-bc2caa27

Finasteride 5 mg vs Placebo: Number of Participants Presenting No Change in Autofluorescence Patterns at the Safety Visit Compared to Baseline

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Finasteride 5 mg vs Placebo: Number of Participants Presenting No Change in Autofluorescence Patterns at the Safety Visit Compared to Baseline. Trial comparisons, record NCT01585441-bc2caa27. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01585441-bc2caa27

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 110.4391wilson
Risk in group 210.3421wilson
Risk difference, group 1 minus group 20-0.5610.658newcombe hybrid score
Risk ratio, group 1 over group 2111log
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Finasteride 5 mg
Participants randomly assigned to the finasteride 5 mg arm were instructed to take one capsule daily for three months.~Finasteride: Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
33OG000
Group 2PlaceboParticipants randomly assigned to the placebo arm will instructed to take one capsule daily for three months.~Placebo: Capsule with no active ingredients to mimic finasteride22OG001

Outcome

Type
SECONDARY
Title
Number of Participants Presenting No Change in Autofluorescence Patterns at the Safety Visit Compared to Baseline
Description
Autofluorescence patterns as observed on Fundus Autofluorescence (FAF) imaging
Time frame
Final Study Visit
Population
One placebo participant was not evaluated at the final safety visit, as the participant completed the study at the Month 3 visit.

Source ClinicalTrials.gov

Trial

Title
Finasteride for Chronic Central Serous Chorioretinopathy
NCT number
NCT01585441
Phases
PHASE2
Conditions
Retinal Disease
Interventions
Finasteride, Placebo
Lead sponsor
National Eye Institute (NEI)
Results first posted
2014-12-04

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01585441-bc2caa27